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Chapter 1: Dementia in the new millennium
John P Wattis
A brief history of our understanding of dementia
Dementia bears a stigma like other mental illnesses. Before effective pharmacological measures for mental illness were developed, that is before the last half of the last century, different models for understanding mental illness and different modes of treatment prevailed. The first positive post-medieval development was that of “moral management” or “moral treatment” of mental illness. Previously belief in demonology or views on the irrationality of people with mental illness had led to abuse and/ or containment. Moral management brought about an engagement with the mentally ill person on an individual and collective level reflected in the modern Therapeutic Community movement. Reasoning and moral and emotional support produced good results in places like the Retreat in York, England and in other countries, too. The era of the large asylum and “medicalisation” of mental illness followed. At the same time, the new discipline of psychoanalysis provided an explanation and treatment for some of the less severe mental disorders and had a wide impact on society. Critiques of an excessively medical model for understanding dementia 1  have led to practical measures of the well being of patients with dementia2 and recommendations for improved models of care 3.

Although conditions described in Roman times probably correspond to current diagnoses of dementia, the modern medical history of the condition begins in 1906 when Alzheimer, a German neuropsychiatrist and associate of Kraeplin, described a woman in late middle age with the clinical picture and pathology of the disease that now bears his name. At another time, he also described the pathology of vascular dementia.  At the time most cases of dementia in old people were written off as “senile” dementia or “senility”. Competing schools of neuropathology in Munich (Alzheimer) and Prague perpetuated this divide and the identity of Alzheimer’s disease with most cases of “senile” dementia was not widely realised for another half century. 

In the mid 1950’s Roth 4 published an account of the natural history of mental disorders in old age that distinguished between “senile” and “arteriosclerotic” psychosis on the basis of their outcomes. Further studies established the epidemiology of mental disorders in late life 5 and the quantitative pathology 6 of Alzheimer’s and vascular dementia. The deficiency of the neurotransmitter acetylcholine in Alzheimer’s disease was recognised ten years later 7 and led to the development of the cholinergic hypothesis and therapies based on it. Initially these were based on attempts to increase the availability of choline by dietary supplementation with the precursor lecithin and subsequently on inhibition of the enzymes responsible for breaking down acetylcholine. In the meantime specialist mental health services for older people were developing and taking an interest in the positive management of people with dementia 8. At this time Alzheimer’s and vascular dementia were regarded as the two main causes of dementia, accounting singly or in combination for 90% or more of all cases (see chapter 2). There were a host of other rarer causes such as Pick’s disease and the “metabolic” dementias of vitamin B12 and thyroid deficiency (see chapter 7). More recently, diffuse Lewy body dementia has been recognised9, though it has still not been included in international diagnostic systems and there is still debate about its precise relationship with Alzheimer’s disease, Parkinson’s disease and other psychiatric disorders10; 11 QUOTE "" . Often different types of pathology co-exist. The “nun study” showed the importance of vascular damage in producing clinical dementia in patients with co-existing Alzheimer pathology 12, confirming earlier pathological studies.


The burden of dementia
Dementia imposes a terrible burden on society. The social burden is greatly influenced by demography since dementia is predominantly a condition of very old people. Since the beginning of the 20th century, the proportion of people in the United Kingdom over the age of 65 has risen threefold. The proportion of very old has increased even more markedly. Other countries in the developed world have been through similar changes and these changes are likely to be experienced in an accelerated way in the developing world (see chapter 2). 

Society may also increase the personal burden on people with dementia and those who care for them by the way it reacts to people with dementia (see chapter 11) and by placing them and their carers under economic pressure. Political decisions about eligibility for care services supported by the state affect the financial burden. There is need for a debate about why old people with dementia should receive less favourable social support than young people with physical disability. For individuals afflicted with dementia the eventual loss of capacity for independent living threatens to take away their autonomy. For family and other carers there is the constant worry about safety and the burden of directly or indirectly meeting the needs of those who find it increasingly difficult to care for themselves. In the UK around three quarters of a million people are currently affected QUOTE "12" 13. In the USA the comparable figure is around four million  QUOTE "13" 14. Currently between 18 and 37 million people worldwide are estimated to have one or other type of dementia and projections suggest that by 2025 this number will nearly double, with nearly three quarters living in developing countries (chapter 2). The cost in terms of lost human potential and burden on caregivers is vast, current annual costs in the USA alone are estimated at over $100 billion. Despite the fact that dementia is concentrated in late life it ranks thirteenth in the World Health Organisation’s list of causes of years lived with disability  QUOTE "14" 15. What can be done about so great a burden?

What we can do 
We need to respond to the challenge at a variety of levels, including the following:
	The international level
	The national level
	The level of the local community
	The level of the family
	The personal level
Internationally, organisations like Alzheimer’s International, the World Health Organisation and the International Psychogeriatric Association are trying to prepare countries in the developing world for the explosion in the prevalence of dementia that an ageing population will bring. In the developed world, there is still a need to eradicate ageist attitudes to the provision of support and treatment for people with dementia. At the population level, our developing knowledge of the risk factors for various forms of dementia may well enable us to produce a relative reduction in the numbers of people affected. However, age itself is the greatest risk factor for developing dementia, especially Alzheimer’s disease and so all those public health and lifestyle measures that increase longevity are likely to increase the population at risk. This does not mean we should give up. Reducing the prevalence of disease and its impact are fundamental tasks for medicine, related disciplines and the whole of society.
The “ideal” scenario would be to develop the capacity to identify people at risk of dementia and to reduce that risk by acceptable and inexpensive public health or specific treatment measures. Genetic risk factors are already identified and will be discussed in more detail in chapters 2 and 3. Measures to eliminate these genes from the gene pool are likely to be impractical, morally unacceptable and have unforeseeable consequences. However, genotyping to identify “at risk” populations may, as our knowledge of the mechanisms of disease expands, enable preventive measures or early treatment at a pre-clinical stage before symptoms of disease develop. As new drugs are developed that interfere with the progression of Alzheimer’s disease and as the population of the developing world ages dilemmas are likely to occur about the affordability of these drugs in poorer countries.
Local communities need to be helped to develop a better understanding of dementia and the issues that surround it so that families and people with dementia are treated as people and not marginalized. Old age psychiatry services, working through local government and primary care services should see this education as one of their functions.
At the family and individual level, positive management requires a bio-psycho-social model. A model that only considers one of these factors is wholly inadequate. Figure 1, taken from “Practical Psychiatry of Old Age” QUOTE "15" 16, emphasises that in dealing with any individual patient we need to take into account brain, body, senses and physical and social environment and the interaction between them. [Insert Figure 1 – Figure 4.1 from PPOA here]. Positive management of dementia consists of first making a diagnosis and excluding rare potentially treatable causes of dementia such as thyroid deficiency.  Specific treatment for Alzheimer’s dementia now exists and is probably effective in some other forms of dementia too though use of the drugs in England is constrained by government guidelines QUOTE "16" 17. The next step is to maximise the patient’s capacity for independent living by optimising physical health, correcting deficiencies in hearing and sight and providing a supportive environment. Emotional and practical support to patients and carers requires collaboration across health and social care organisations. This kind of multi-layered approach fostered and was strengthened by the multi-disciplinary approach to old age mental health services developed in the UK  QUOTE "17-19" 18-20 QUOTE ""  QUOTE "" . Other interventions, psychological and pharmacological, are required to cope with the depression and behavioural problems sometimes found in people with dementia. 

However, even in the UK, one of the first countries to develop specific old age psychiatry services, there is a “clinical iceberg”. The majority of people with dementia never come to the attention of those specialist services. There is a major need for specialist services to wok together with primary care to improve access to those specialist services for people with dementia. The arrival of drugs for the treatment of Alheimer’s diseasehas increased the number of referrals and, in the UK, specialist memory clinics are increasing in number to cope with increased demand 21.

Future directions
The first useful anti-dementia drugs, the cholinesterase inhibitors, have now been available for over five years. These drugs (tacrine, donepezil, rivastigmine, galantamine and others) interfere with the breakdown of acetylcholine, effectively amplifying its effect at the synaptic cleft. Memantine, a drug with a completely different mode of action, has also been licensed in the United Kingdom for moderate-severe dementia of the Alzheimer type. Other existing drugs such as the non-steroidal anti-inflammatory drugs, oestrogens and nicotine may also have some effect on Alzheimer’s dementia. It seems likely that anti-platelet drugs will help some patients with vascular dementia though this has yet to be convincingly demonstrated. Drugs currently in development may affect the development of the insoluble form of beta amyloid by inhibiting some of the enzymes that split amyloid precursor protein. Attempts to deal with amyloid by inducing an immune response have had to be abandoned because, in clinical trials, they appeared to induce an immune response to other parts of the central nervous system. Other lines of enquiry, especially into the genetic risk factors for Alzheimer’s and other dementias are likely to suggest further therapeutic avenues. The herbal preparation, Gingko biloba, has also been shown to have some positive effect in Alzheimer’s disease though the mechanism of action is not clear. If we did understand it better, perhaps this too would suggest other lines of approach.

Nor does the future only lie in developing new drugs. Basic science may help us understand the processes that precede the clinical symptoms of Alzheimer’s disease and may suggest preventative measures we cannot anticipate. Psychological and social care for people with dementia will develop. Indeed we could improve considerably on our current practical care for people with dementia by implementing what we already know and by educating those involved in providing care to people with dementia in the principles of person centred care  QUOTE "21" 22. Improving the organisation and management of care should not be neglected either. This requires a more adequate political and social response to the challenges posed by an ageing society.

Practical Management of Dementia

The scope of what we currently can do is very wide and this book seeks to explore that scope. It does not look in detail at the anti-dementia drugs though these are mentioned briefly in chapter 12, on memory clinics. We have asked contributors to cover epidemiology (the science of the distribution of disease in populations), and the current classification of the dementias into different diagnoses with different causes, time courses and (potentially) treatments. Building on that foundation, we have looked at the practical science of early detection and diagnosis. We have also taken a variety of perspectives: those of the psychiatrist, clinical psychologist, physician for the elderly, the general practitioner, the nurse, the occupational therapist and the social worker. We have explored the role of the “Memory Clinic” and the special issues of early onset dementia. We have also asked contributors to discuss the legal framework in which we manage dementia (principally from the point of view of English law) and to share neglected but developing knowledge about the spiritual aspects of dementia and its management. Finally we have commissioned a chapter to discuss how comprehensive and integrated mental health services for people with dementia might be developed, rooted largely in practice in the United Kingdom. As in any edited work we are conscious of some repetitions but in an effort to make each chapter reasonably self-sufficient we have not tried to eliminate these.





	The modern “bio-medical” understanding of dementia is only a century old
	It is inadequate without a broader “psycho-social” approach 
	The burden on society from dementia is related to an ageing population
	The burden on individuals with dementia and their carers is worsened by ageism manifested in reduced support when compared with chronic disabilities affecting younger people
	International and national action is needed to meet the political and economic challenges of an ageing population and an increased prevalence of dementia.
	Local communities can respond with more understanding if old age services make education part of their task
	Families and people with dementia can be helped by an integrated biological, psychological and social approach in a multidisciplinary framework
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